Cellular and molecular gastroenterology and hepatology · 2026
Interleukin13 Ameliorates Hepatocellular Steatosis via Interleukin13Rα1-c-Jun N-Terminal Kinase-FOS-Like Antigen 2 Signaling Pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
von Bülow Verena, Felske Dejan A, Riebeling Sarah B, Schmidt Fabian P, Stettler Frederik, Schmid Andreas, Karrasch Thomas, Eder Klaus, Most Erika, Morlock Gertrud, Haase Annika, Bier Jens, Hermanns Heike M, Geier Andreas, Tuffs Christopher, Pons-Kühnemann Jörn, Roderfeld Martin, Roeb Elke
Аннотация
BACKGROUND & AIMS: Severe obesity is a major global health challenge and a key driver of hepatic steatosis through systemic insulin resistance and enhanced de novo lipogenesis. Excessive hepatic triglyceride accumulation represents a central metabolic consequence of this condition. This study aimed to identify immune-derived regulators of liver lipid metabolism and to define the mechanistic role of interleukin13 in obesity-associated liver disease progression.
METHODS: Interleukin13 levels and related signaling pathways were analyzed in plasma samples from patients with ≥class II obesity and liver biopsies from patients with hepatic steatosis and steatohepatitis. The effects of interleukin13 depletion on lipid metabolism were examined in mice, whereas its mechanistic role in fat metabolism was studied in primary hepatocytes.
RESULTS: In a cohort of severely obese patients, plasma interleukin13 levels rose after weight loss and were positively associated with fibroblast growth factor 19, fibroblast growth factor 21, and insulin-like growth factor-1. Interleukin13-deficient mice showed worsened liver triglyceride accumulation, lower polyunsaturated fatty acids, and altered expression of peroxisome proliferator-activated receptor-dependent lipid genes. Primary murine hepatocytes revealed that interleukin13 decreases triglyceride content through interleukin13Rα1 and a c-Jun N-terminal kinase-dependent c-JUN-FOS-like antigen 2 axis, which enhances β-oxidation and ketogenesis. FOS-like antigen 2 was required for maximal peroxisome proliferator-activated receptor activity and was upregulated in livers of patients with hepatic steatosis and steatohepatitis.
CONCLUSIONS: These data demonstrate that interleukin13 is a critical immunometabolic regulator of hepatic lipid homeostasis. Targeting the interleukin13-FOS-like antigen 2-peroxisome proliferator-activated receptor signaling pathway may offer a novel therapeutic approach to reduce hepatic steatosis.
METHODS: Interleukin13 levels and related signaling pathways were analyzed in plasma samples from patients with ≥class II obesity and liver biopsies from patients with hepatic steatosis and steatohepatitis. The effects of interleukin13 depletion on lipid metabolism were examined in mice, whereas its mechanistic role in fat metabolism was studied in primary hepatocytes.
RESULTS: In a cohort of severely obese patients, plasma interleukin13 levels rose after weight loss and were positively associated with fibroblast growth factor 19, fibroblast growth factor 21, and insulin-like growth factor-1. Interleukin13-deficient mice showed worsened liver triglyceride accumulation, lower polyunsaturated fatty acids, and altered expression of peroxisome proliferator-activated receptor-dependent lipid genes. Primary murine hepatocytes revealed that interleukin13 decreases triglyceride content through interleukin13Rα1 and a c-Jun N-terminal kinase-dependent c-JUN-FOS-like antigen 2 axis, which enhances β-oxidation and ketogenesis. FOS-like antigen 2 was required for maximal peroxisome proliferator-activated receptor activity and was upregulated in livers of patients with hepatic steatosis and steatohepatitis.
CONCLUSIONS: These data demonstrate that interleukin13 is a critical immunometabolic regulator of hepatic lipid homeostasis. Targeting the interleukin13-FOS-like antigen 2-peroxisome proliferator-activated receptor signaling pathway may offer a novel therapeutic approach to reduce hepatic steatosis.